Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034580 · ClinicalTrials.gov registry record · Phase 4
Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 326
- Enrollment target
NCT00034580 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 326 participants.
The verdict
NCT00034580, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 326 participants
- Enrollment target
Study Summary
This is a research study comparing the safety and efficacy of two active study medications for the treatment of bipolar I disorder.
Interventions
- DRUG risperidone
- DRUG olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2001-08 |
| Est. Completion | 2002-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00034580
The ClinicalTrials.gov registry entry for NCT00034580 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which risperidone is the first listed.
NCT00034580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00034580 about?
NCT00034580 is a clinical study titled "Olanzapine Versus Active Comparator in the Treatment of Bipolar I Disorder". This is a research study comparing the safety and efficacy of two active study medications for the treatment of bipolar I disorder.
What is the current status of trial NCT00034580?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 326 participants. The study started on 2001-08. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00034580?
The interventions under investigation include: risperidone (DRUG), olanzapine (DRUG).
Who is sponsoring clinical trial NCT00034580?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.